News & Updates

In a national cohort study in Singapore, a booster dose of BNT162b2 maintained individual protection against severe COVID-19 disease among adolescents aged 12–17 years.

A brain MRI–based artificial intelligence (AI) tool developed by researchers from the Chinese University of Hong Kong (CUHK) outperforms MRI markers such as hippocampal volume (HV) in predicting syndromal conversion of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia, according to new data presented at Advances in Medicine (AIM) 2023.

In patients with chronic hepatitis B (CHB) without cirrhosis, the rates of hepatitis B surface antigen (HBsAg) loss appear to be higher after discontinuation of tenofovir disoproxil fumarate (TDF) than of entecavir, and this is particularly true for patients who have not experienced relapse after treatment discontinuation, according to a study.

For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.

The addition of information on migraine with aura (MA) status to the cardiovascular disease (CVD) risk prediction algorithms results in a better model fit but falls short of substantially improving risk stratification among women, according to a study.

In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.